MovDisordV3, PascalFrancis, Corpus, bibRecord, 000784

Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study

Identifieur interne : 000784 ( PascalFrancis/Corpus ); précédent : 000783; suivant : 000785

Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study

Auteurs : Iria Cabo Lopez ; Pedro J. Garcia Ruiz ; Silvia Vázquez Fernandez Del Pozo ; Vicenta Sanchez Bernardos

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:11-0065110

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Dyskinésie, Pathologie du système nerveux, Complication, Etude longitudinale, Fluctuation, Prospective.

English descriptors

KwdEn :
- Complication, Dyskinesia, Fluctuations, Follow up study, Nervous system diseases, Parkinson disease, Prospective.

Abstract

Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1 %). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 16`
A08	`01`	`1`	`ENG`	`@1 Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study`
A11	`01`	`1`		`@1 CABO LOPEZ (Iria)`
A11	`02`	`1`		`@1 GARCIA RUIZ (Pedro J.)`
A11	`03`	`1`		`@1 FERNANDEZ DEL POZO (Silvia Vázquez)`
A11	`04`	`1`		`@1 SANCHEZ BERNARDOS (Vicenta)`
A14	`01`			`@1 Department of Neurology, Fundación Jiménez Díaz @2 Madrid @3 ESP @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Universidad Autónoma de Madrid (UAM) @3 ESP @Z 1 aut. @Z 2 aut.`
A14	`03`			`@1 CIBERNED @3 ESP @Z 1 aut. @Z 2 aut.`
A14	`04`			`@1 Department of Epidemiology, Fundación Jiménez Díaz @2 Madrid @3 ESP @Z 3 aut.`
A20				`@1 2735-2739`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000193512620060`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 11-0065110`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1 %). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Complication @5 09`
C03	`04`	`X`	`ENG`	`@0 Complication @5 09`
C03	`04`	`X`	`SPA`	`@0 Complicación @5 09`
C03	`05`	`X`	`FRE`	`@0 Etude longitudinale @5 10`
C03	`05`	`X`	`ENG`	`@0 Follow up study @5 10`
C03	`05`	`X`	`SPA`	`@0 Estudio longitudinal @5 10`
C03	`06`	`X`	`FRE`	`@0 Fluctuation @5 11`
C03	`06`	`X`	`ENG`	`@0 Fluctuations @5 11`
C03	`06`	`X`	`SPA`	`@0 Fluctuación @5 11`
C03	`07`	`X`	`FRE`	`@0 Prospective @5 12`
C03	`07`	`X`	`ENG`	`@0 Prospective @5 12`
C03	`07`	`X`	`SPA`	`@0 Prospectiva @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Mouvement involontaire @5 42`
C07	`05`	`X`	`ENG`	`@0 Involuntary movement @5 42`
C07	`05`	`X`	`SPA`	`@0 Movimiento involuntario @5 42`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 43`
N21				`@1 045`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0065110 INIST
ET :	Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study
AU :	CABO LOPEZ (Iria); GARCIA RUIZ (Pedro J.); FERNANDEZ DEL POZO (Silvia Vázquez); SANCHEZ BERNARDOS (Vicenta)
AF :	Department of Neurology, Fundación Jiménez Díaz/Madrid/Espagne (1 aut., 2 aut., 4 aut.); Universidad Autónoma de Madrid (UAM)/Espagne (1 aut., 2 aut.); CIBERNED/Espagne (1 aut., 2 aut.); Department of Epidemiology, Fundación Jiménez Díaz/Madrid/Espagne (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 16; Pp. 2735-2739; Bibl. 21 ref.
LA :	Anglais
EA :	Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1 %). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Dyskinésie; Pathologie du système nerveux; Complication; Etude longitudinale; Fluctuation; Prospective
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique
ED :	Parkinson disease; Dyskinesia; Nervous system diseases; Complication; Follow up study; Fluctuations; Prospective
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder
SD :	Parkinson enfermedad; Disquinesia; Sistema nervioso patología; Complicación; Estudio longitudinal; Fluctuación; Prospectiva
LO :	INIST-20953.354000193512620060
ID :	11-0065110

Links to Exploration step

Pascal:11-0065110

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study</title>
<author><name sortKey="Cabo Lopez, Iria" sort="Cabo Lopez, Iria" uniqKey="Cabo Lopez I" first="Iria" last="Cabo Lopez">Iria Cabo Lopez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Universidad Autónoma de Madrid (UAM)</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>CIBERNED</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garcia Ruiz, Pedro J" sort="Garcia Ruiz, Pedro J" uniqKey="Garcia Ruiz P" first="Pedro J." last="Garcia Ruiz">Pedro J. Garcia Ruiz</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Universidad Autónoma de Madrid (UAM)</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>CIBERNED</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fernandez Del Pozo, Silvia Vazquez" sort="Fernandez Del Pozo, Silvia Vazquez" uniqKey="Fernandez Del Pozo S" first="Silvia Vázquez" last="Fernandez Del Pozo">Silvia Vázquez Fernandez Del Pozo</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Epidemiology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sanchez Bernardos, Vicenta" sort="Sanchez Bernardos, Vicenta" uniqKey="Sanchez Bernardos V" first="Vicenta" last="Sanchez Bernardos">Vicenta Sanchez Bernardos</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0065110</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 11-0065110 INIST</idno>
<idno type="RBID">Pascal:11-0065110</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000784</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study</title>
<author><name sortKey="Cabo Lopez, Iria" sort="Cabo Lopez, Iria" uniqKey="Cabo Lopez I" first="Iria" last="Cabo Lopez">Iria Cabo Lopez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Universidad Autónoma de Madrid (UAM)</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>CIBERNED</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garcia Ruiz, Pedro J" sort="Garcia Ruiz, Pedro J" uniqKey="Garcia Ruiz P" first="Pedro J." last="Garcia Ruiz">Pedro J. Garcia Ruiz</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Universidad Autónoma de Madrid (UAM)</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>CIBERNED</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fernandez Del Pozo, Silvia Vazquez" sort="Fernandez Del Pozo, Silvia Vazquez" uniqKey="Fernandez Del Pozo S" first="Silvia Vázquez" last="Fernandez Del Pozo">Silvia Vázquez Fernandez Del Pozo</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Epidemiology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sanchez Bernardos, Vicenta" sort="Sanchez Bernardos, Vicenta" uniqKey="Sanchez Bernardos V" first="Vicenta" last="Sanchez Bernardos">Vicenta Sanchez Bernardos</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Complication</term>
<term>Dyskinesia</term>
<term>Fluctuations</term>
<term>Follow up study</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prospective</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Complication</term>
<term>Etude longitudinale</term>
<term>Fluctuation</term>
<term>Prospective</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1 %). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>16</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CABO LOPEZ (Iria)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GARCIA RUIZ (Pedro J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FERNANDEZ DEL POZO (Silvia Vázquez)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SANCHEZ BERNARDOS (Vicenta)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Universidad Autónoma de Madrid (UAM)</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>CIBERNED</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Epidemiology, Fundación Jiménez Díaz</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>2735-2739</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193512620060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0065110</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1 %). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Complication</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Complication</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Complicación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Fluctuation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Fluctuations</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Fluctuación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Prospective</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Prospective</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fN21><s1>045</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0065110 INIST</NO>
<ET>Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study</ET>
<AU>CABO LOPEZ (Iria); GARCIA RUIZ (Pedro J.); FERNANDEZ DEL POZO (Silvia Vázquez); SANCHEZ BERNARDOS (Vicenta)</AU>
<AF>Department of Neurology, Fundación Jiménez Díaz/Madrid/Espagne (1 aut., 2 aut., 4 aut.); Universidad Autónoma de Madrid (UAM)/Espagne (1 aut., 2 aut.); CIBERNED/Espagne (1 aut., 2 aut.); Department of Epidemiology, Fundación Jiménez Díaz/Madrid/Espagne (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 16; Pp. 2735-2739; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1 %). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Dyskinésie; Pathologie du   système nerveux; Complication; Etude longitudinale; Fluctuation; Prospective</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Mouvement involontaire; Trouble neurologique</FG>
<ED>Parkinson disease; Dyskinesia; Nervous system diseases; Complication; Follow up study; Fluctuations; Prospective</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder</EG>
<SD>Parkinson enfermedad; Disquinesia; Sistema nervioso patología; Complicación; Estudio longitudinal; Fluctuación; Prospectiva</SD>
<LO>INIST-20953.354000193512620060</LO>
<ID>11-0065110</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000784 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000784 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0065110
   |texte=   Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study

Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri